Literature DB >> 17384285

Doxorubicin-induced MAPK activation in hepatocyte cultures is independent of oxidant damage.

Rosaura Navarro1, Rosa Martínez, Idoia Busnadiego, M Begoña Ruiz-Larrea, José Ignacio Ruiz-Sanz.   

Abstract

Doxorubicin (DOX) is a potent anticancer drug, whose clinical use is limited on account of its toxicity. DOX cytotoxic effects have been associated with reactive oxygen species (ROS) generated during drug metabolism. ROS induce signaling cascades leading to changes in the phosphorylation status of target proteins, which are keys for cell survival or apoptosis. The mitogen-activated protein kinase (MAPK) cascades are routes activated in response to oxidative stress. In this work, the effects of DOX on cytotoxicity, indicators of oxidative stress (malondialdehyde -MDA- and GSH), and the phosphorylation status of extracellular signal-regulated kinases (ERKs), c-Jun N-terminal kinases (JNKs), and p38 kinases were analyzed in primary cultures of rat hepatocytes. DOX (1-50 microM) did not modify lactate dehydrogenase (LDH) release into the medium, the levels of MDA (determined by high-performance liquid chromatography [HPLC]) or the intracellular GSH during the incubation time up to 6 h. GSH levels from mitochondria extracted by Percoll gradient from cultured hepatocytes were not modified by DOX, thus excluding its depletion or any impaired mitochondrial uptake. Characterization of proteins by Western blot analysis revealed that DOX increased phosphorylation of p38 kinases and JNK1 and JNK2 in a dose- and time-dependent manner. DOX also increased ERK2 phosphorylation at latter time points. In conclusion, DOX triggers activation of ERK, JNK, and p38 kinases in primary cultures of rat hepatocytes independently of oxidant damage.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17384285     DOI: 10.1196/annals.1378.044

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  7 in total

1.  Small-Molecule NSC59984 Induces Mutant p53 Degradation through a ROS-ERK2-MDM2 Axis in Cancer Cells.

Authors:  Shengliang Zhang; Lanlan Zhou; Wafik S El-Deiry
Journal:  Mol Cancer Res       Date:  2022-04-01       Impact factor: 5.852

2.  ZAK is required for doxorubicin, a novel ribotoxic stressor, to induce SAPK activation and apoptosis in HaCaT cells.

Authors:  Kristin A D Sauter; Eli A Magun; Mihail S Iordanov; Bruce E Magun
Journal:  Cancer Biol Ther       Date:  2010-08-13       Impact factor: 4.742

3.  Doxorubicin induces cytotoxicity through upregulation of pERK-dependent ATF3.

Authors:  Eun-Jung Park; Hyuk-Kwon Kwon; Yong-Min Choi; Hyeon-Jun Shin; Sangdun Choi
Journal:  PLoS One       Date:  2012-09-13       Impact factor: 3.240

4.  Piper and Vismia species from Colombian Amazonia differentially affect cell proliferation of hepatocarcinoma cells.

Authors:  Leandro J Lizcano; Maite Siles; Jenifer Trepiana; M Luisa Hernández; Rosaura Navarro; M Begoña Ruiz-Larrea; José Ignacio Ruiz-Sanz
Journal:  Nutrients       Date:  2014-12-30       Impact factor: 5.717

5.  SIRT7 regulates hepatocellular carcinoma response to therapy by altering the p53-dependent cell death pathway.

Authors:  Jie Zhao; Ann Wozniak; Abby Adams; Josiah Cox; Anusha Vittal; Jordan Voss; Brian Bridges; Steven A Weinman; Zhuan Li
Journal:  J Exp Clin Cancer Res       Date:  2019-06-13

6.  IL-17A Increases Doxorubicin Efficacy in Triple Negative Breast Cancer.

Authors:  Nicholas R Hum; Aimy Sebastian; Kelly A Martin; Naiomy D Rios-Arce; Sean F Gilmore; David M Gravano; Elizabeth K Wheeler; Matthew A Coleman; Gabriela G Loots
Journal:  Front Oncol       Date:  2022-07-18       Impact factor: 5.738

7.  MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells.

Authors:  Andrea Turner; Liang-Cheng Li; Tania Pilli; Lixia Qian; Elizabeth Louise Wiley; Suman Setty; Konstantin Christov; Lakshmy Ganesh; Ajay V Maker; Peifeng Li; Prasad Kanteti; Tapas K Das Gupta; Bellur S Prabhakar
Journal:  PLoS One       Date:  2013-02-15       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.